Navigation Links
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Date:1/6/2014

SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study. The pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 as assessed by central blinded video raters.

At Week 6, AIMS scores were reduced by 2.6 points in the NBI-98854 intention-to-treat (ITT) group compared to a reduction of 0.2 points in the placebo arm (p<0.001). Additionally, the responder rate (>= 50% improvement from baseline) was 49% in the NBI-98854 ITT group compared to 18% in placebo (p=0.002). In the per-protocol (PP) group AIMS scores were reduced by 3.3 points for those subjects taking NBI-98854 (p<0.001), with a corresponding responder rate of 59% (p<0.001).

"The profound response in this Kinect 2 study demonstrates the potential of NBI-98854 as both a safe and highly effective treatment for patients suffering from tardive dyskinesia," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences. "It is clear from these results that the use of blinded central AIMS raters coupled with the ability to titrate up to 75 mg of NBI-98854 were both critical to the success of this trial."

The improvement in Week 6 AIMS was also corroborated by the Clinical Global Impression–Tardive Dyskinesia (CGI-TD). Treating clinicians determined that approximately 67% of the subjects taking NBI-98854 were "much improved" or "very much improved" at Week 6 compared to only 16% of the placebo subjects (p<0.001) in this pre-specified key secondary efficacy endpoint.

"The data from this Kinect 2 study allows us to submit an
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
3. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
4. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
7. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
8. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015   Today: A ... teens nationwide has prompted The Addiction Advisor to ... usage in just 5 minutes. The drug screening ... tools to drug test for thirteen (13) of ... in confidential packaging with instructions and recommendations, parents ...
(Date:6/3/2015)... -- PARI Respiratory Equipment has won a 2015 American Package Design ... the FDA on December 2, is the first co-packaging of ... Nebulizer for patients with cystic fibrosis. ... this unique product offering of nebulized drug and device.  In ... we also wanted to convey that the components suit each ...
(Date:6/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t3kkhg/the_future_of ) ... Future of Pharmaceutical Outsourcing" report to their ... desperate need to develop better drugs with high ... been increasingly utilizing external resources to increase their ... their internal operation. Their outsourcing demands and proportions ...
Breaking Medicine Technology:The Drug Detective Is A Simple Test That Could Save Your Child's Life 2Kitabis Pak Wins American Package Design Award 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... MedShape Solutions, Inc., the industry leader in ... has developed new, larger sizes of its ExoShape ... that simplifies and improves soft tissue graft fixation ... announcement comes after MedShape received the U.S. Food ...
... ActiveCare, Inc. (ACAR.OB) a leader in senior care technology, ... up the rollout of ActiveCare,s ActiveHome products and services ... its, comprehensive ActiveHome Monitoring System.  To guide this market ... his team has extensive experience increasing sales and marketing ...
Cached Medicine Technology:MedShape Solutions, Inc. Announces Extension of ExoShape™ Product Line in Response to Surgeon Demand 2With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing 2With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing 3
(Date:6/3/2015)... 2015 Johnson & Johnson and its ... to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) filed ... allegedly used to market the antipsychotic drug. Court ... the Arkansas Attorney General moved to dismiss the case ... Risperdal settlement amounts to just a fraction of the ...
(Date:6/3/2015)... 03, 2015 “ Harmony ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... wants to improve some aspect of their life. , A ... for people with difficulties in their life. However, hypnotherapy is ...
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... 03, 2015 On the heels of a ... industry by 2020 ( click here to review news ... believe Baltimore has the talent to become a ... genetic code and other biological data are collected and analyzed ... “Baltimore contains all the elements of a perfect storm for ...
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Dr. Steven ... York Cardiac Diagnostic Center ( http://www.newyorkcardiac.com ) located in NYC, ... on weekdays to his practice. In most cases, depending on ... of the day they call, they will be seen by ... first priority as a cardiologist is to ensure that people ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2
... ... Institute to identify regions of the dengue virus and Mycobacterium tuberculosis that can be targeted ... Melbourne, ... (NASDAQ Capital Market: CBTE), is pleased to announce that it has been awarded a major ...
... , NASDAQ: CRME ... Pharma Corp. (NASDAQ: CRME / TSX: COM) today ... its directors, officers and employees (each a "restricted person") to ... pursuant to applicable Canadian and U.S. securities laws, including the ...
... Researchers from Boston University School of Medicine (BUSM) have ... of emphysema. The study, which appears on-line in the ... therapeutic genes in lung tissue for a lifetime after only ... most common inherited form of emphysema seen in young people ...
... less clogged in those who nurse infants, study finds, , ... to breast-feed because of the numerous health benefits it offers ... the health of the mothers, hearts later in life. ... that those who had not breast-fed were much more likely ...
... ... rid of their worst menopause and perimenopause symptoms. Don’t Pause contains other natural supplements ... women experience as they age. , ... (PRWEB) December 21, 2009 -- When a woman starts going through ...
... , NEW YORK, Dec. 21 The Center to Advance ... Diane E. Meier, MD , a pioneer in palliative care, has ... of four 2009-2010 Health and Aging Policy Fellows , Dr. ... process at the Federal level. The HELP committee has jurisdiction over ...
Cached Medicine News:Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 2Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 3Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 4Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 2Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 3Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 4Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 5Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 6Health News:Researchers discover gene therapy to prevent progression of emphysema 2Health News:Breast-Feeding May Protect a Woman's Heart 2Health News:Breast-Feeding May Protect a Woman's Heart 3Health News:Women Turn to Natural Menopause Remedies for Safe, Effective Relief 2Health News:Women Turn to Natural Menopause Remedies for Safe, Effective Relief 3Health News:Center to Advance Palliative Care Director and MacArthur Recipient, Diane E. Meier, MD, Accepts Fellowship Post With Senate HELP Committee 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: